Today: 23 May 2026
Mastercard stock slides as Trump credit-card rate cap talk keeps pressure on MA
14 January 2026
2 mins read

Mastercard stock slides as Trump credit-card rate cap talk keeps pressure on MA

New York, January 13, 2026, 17:40 EST — After-hours

  • Mastercard shares dropped roughly 3.8% Tuesday, following a wider slump in card and bank stocks
  • Investors are digesting the impact of a proposed one-year 10% cap on credit-card interest rates
  • Mastercard will release its quarterly earnings on Jan. 29

Shares of Mastercard dropped 3.8% on Tuesday, slipping further to $544.99 in after-hours trades. The decline came amid investor concerns over President Donald Trump’s plan to limit credit-card interest rates. Visa also took a hit, falling 4.5% during the regular session.

The policy threat arrives at a tricky time for markets. Big banks are reporting earnings this week, while traders scramble to figure out how a rate cap might affect credit availability and consumer spending.

The cap on annual percentage rates, or APRs, targets banks that issue cards, not the payment networks. Investors worry that issuers might respond by cutting credit limits or shutting accounts, which could reduce transaction volumes and hit Mastercard’s fee income.

JPMorgan Chief Financial Officer Jeremy Barnum warned the proposal would be “very bad for consumers, very bad for the economy,” adding the bank would need to scale back the credit it provides. Barnum noted the move is developing “very quickly” and “starting with a social media post,” as Trump also backed reducing card swipe fees—the charges merchants pay to accept cards. Reuters

Credit card debt stacks up quickly since it’s “revolving credit,” allowing balances to roll over each month with interest adding on if only minimum payments are made. U.S. credit card balances hit $1.23 trillion by the end of Q3, according to Reuters. Reuters

Some investors doubt the politics will progress much further. UBS analysts pointed out that implementing rate caps would require an Act of Congress, warning that an executive order would probably face intense legal battles. Still, the uncertainty has weighed on financial stocks.

Analyst opinions are beginning to diverge. Compass Point upgraded Mastercard from Neutral to Buy, lifting its price target to $735 from $620. The firm cited a potential sector rebound following fourth-quarter results.

Mizuho’s Dan Dolev and analysts at Morgan Stanley suggested the impact on card networks may not be as severe as initially thought. Dolev highlighted a potential move toward debit cards and “buy now, pay later” options, both of which still bring in fee income. Barron’s

Mastercard announced it will report its fourth-quarter and full-year 2025 earnings on Jan. 29, with a conference call scheduled for 9:00 a.m. Eastern.

Separately, Mastercard announced a collaboration with travel platform Agoda to develop a loyalty redemption tool. This tool integrates Agoda’s travel inventory into Mastercard’s Global Redemption Suite, offering cardholders greater flexibility in using their points.

Washington remains the key wildcard. Should the rate cap gain momentum—or if swipe fee cuts move from chatter to law—lenders might overhaul card economics, impacting spending, rewards, and network fees. If those efforts falter, the sector’s steep selloff could reverse just as fast.

Next in focus: any updates from the White House or Congress before the proposed Jan. 20 start date, plus Mastercard’s Jan. 29 earnings report for insights on holiday shopping and cross-border payment patterns.

Stock Market Today

  • UBS Boosts Jazz Pharma Stock Price Target to $307 Ahead of FDA Decision
    May 23, 2026, 2:29 PM EDT. UBS upgraded Jazz Pharmaceuticals (JAZZ) stock from neutral to buy, raising its price target by 63% to $307 from $188. This surge exceeds the prior consensus of $242 and follows strong Q1 results, with revenue up 19% year-over-year and oncology portfolio growth of 45%. The move anticipates FDA approval on August 25 of Zanidatamab (Ziihera) for HER2-positive gastroesophageal cancer, expected to generate peak sales of $3.1 billion. UBS projects 10% revenue and 11% earnings growth from 2026-2030, versus consensus of around 7% and 6%, and supports a valuation multiple increase from 7x to 10x earnings, reflecting confidence in sustainable growth. Key risks include FDA delays, slower oncology sales ramp, and underperformance of core franchises like Xywav and Epidiolex.

Latest articles

AbbVie Shares Edge Up Ahead Of Holiday On Pipeline News

AbbVie Shares Edge Up Ahead Of Holiday On Pipeline News

23 May 2026
AbbVie shares closed Friday at $215.70, up 0.56%, gaining 2.5% for the week. The company reported a positive European panel recommendation for MAVIRET in acute hepatitis C and released new oncology data ahead of the ASCO meeting. U.S. markets are closed Monday for Memorial Day, with trading set to resume Tuesday.
Coherent Shares Trade Close to $378, With Next Test Set for Tuesday After Volatile AI-Optics Week

Coherent Shares Trade Close to $378, With Next Test Set for Tuesday After Volatile AI-Optics Week

23 May 2026
Coherent Corp. shares closed at $377.57 Friday, down 0.1% for the day and 1.3% below last week, underperforming the S&P 500 and Nasdaq ahead of the Memorial Day market closure. The company reported fiscal Q3 revenue of $1.81 billion, up 21% year-over-year, with strong demand in datacenter and communications. Nvidia invested $2 billion in March and signed a multi-year optics agreement. Coherent trades at 179 times trailing earnings.
Intuit Slashes 3,000 Jobs as TurboTax Faces New AI Threats

Intuit Slashes 3,000 Jobs as TurboTax Faces New AI Threats

23 May 2026
Intuit will cut about 3,000 jobs, or 17% of its workforce, and close offices in Reno and Woodland Hills as it restructures to focus on artificial intelligence. The company expects $300 million to $340 million in charges, mostly in the fiscal fourth quarter. Intuit raised full-year revenue guidance but lowered its TurboTax outlook, citing pressure from low-cost AI tools. Shares last traded at $319.94 after a volatile week.
Palantir stock (PLTR) slips after hours as Feb. 2 earnings date set and Citi turns bullish
Previous Story

Palantir stock (PLTR) slips after hours as Feb. 2 earnings date set and Citi turns bullish

CoreWeave stock (CRWV) slips after-hours as CEO bats away Nvidia ‘circular financing’ fears
Next Story

CoreWeave stock (CRWV) slips after-hours as CEO bats away Nvidia ‘circular financing’ fears

Go toTop